Bayer set to spend $3.4M this year to expand its Indonesian operations

German pharmaceutical giant Bayer said it expects to spend $3.4 million to expand its Indonesian production capacity for effervescents this year.

The company has already dropped $8.8 million since early last year to build out its warehousing and production capacity in the country, the Jakarta Post reports. That new warehouse facility, which is located at Bayer's 102,000-square-meter production facility area in Cimanggis, Depok, will be able to accommodate all its pharmaceutical production with 7,000 pallets, double the current 3,500 pallets.

"The new facility is expected to start production next year," Bayer Indonesia president director Ashraf Al-Ouf told the newspaper.

The Indonesian operation has set a target to increase the production capacity of its effervescent operation, filling up to 45 million tubes per year from the current 36.3 million tubes.

The Bayer facility produces multivitamin effervescent tablets under the Redoxon and Calcium D Redoxon (CDR) brand names. In Indonesia, the tablets compete with PT Konimex's Protecal Defense and PT Pyridam Farma's Holisticare Ester-C. Bayer also produces analgesic drugs aspirin and Saridon as well as antifungal cream Canesten.

- read the Jakarta Post story

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.